JP2010525805A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010525805A5 JP2010525805A5 JP2010505002A JP2010505002A JP2010525805A5 JP 2010525805 A5 JP2010525805 A5 JP 2010525805A5 JP 2010505002 A JP2010505002 A JP 2010505002A JP 2010505002 A JP2010505002 A JP 2010505002A JP 2010525805 A5 JP2010525805 A5 JP 2010525805A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- nucleic acid
- acid construct
- promoter
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 102000040430 polynucleotide Human genes 0.000 claims 5
- 108091033319 polynucleotide Proteins 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- 241000701161 unidentified adenovirus Species 0.000 claims 5
- 230000037396 body weight Effects 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 230000003362 replicative effect Effects 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 230000033115 angiogenesis Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 1
- 102100033902 Endothelin-1 Human genes 0.000 claims 1
- 101800004490 Endothelin-1 Proteins 0.000 claims 1
- 241001135569 Human adenovirus 5 Species 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 108700008625 Reporter Genes Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 229960004308 acetylcysteine Drugs 0.000 claims 1
- 239000002870 angiogenesis inducing agent Substances 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 239000003145 cytotoxic factor Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 230000001023 pro-angiogenic effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/790,992 US20070286845A1 (en) | 2000-11-17 | 2007-04-30 | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| PCT/IL2008/000543 WO2008132729A2 (en) | 2007-04-30 | 2008-04-27 | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010525805A JP2010525805A (ja) | 2010-07-29 |
| JP2010525805A5 true JP2010525805A5 (https=) | 2011-05-26 |
Family
ID=38895566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010505002A Pending JP2010525805A (ja) | 2007-04-30 | 2008-04-27 | 内皮細胞特異性を示すプロモーター及びそのプロモーターを使って血管形成を制御する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20070286845A1 (https=) |
| EP (1) | EP2152317A4 (https=) |
| JP (1) | JP2010525805A (https=) |
| KR (1) | KR101525548B1 (https=) |
| CN (2) | CN103276015A (https=) |
| AU (1) | AU2008243817B2 (https=) |
| CA (1) | CA2685394A1 (https=) |
| MX (1) | MX2009011750A (https=) |
| NZ (1) | NZ581511A (https=) |
| WO (1) | WO2008132729A2 (https=) |
| ZA (1) | ZA200908331B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100282634A1 (en) * | 2000-11-17 | 2010-11-11 | Dror Harats | Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis |
| AU2003222427B8 (en) | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| US8071740B2 (en) | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| US8039261B2 (en) * | 2000-11-17 | 2011-10-18 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| CN100506284C (zh) * | 2001-10-19 | 2009-07-01 | 脉管生物生长有限公司 | 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法 |
| EP2310507A4 (en) * | 2008-07-08 | 2013-03-20 | David Gladstone Inst | METHOD AND COMPOSITIONS FOR ANGIOGENIC MODULATION |
| AU2011204407B2 (en) * | 2010-01-05 | 2015-05-07 | Vascular Biogenics Ltd. | Compositions and methods for treating glioblastoma GBM |
| NZ601324A (en) * | 2010-01-05 | 2014-10-31 | Vascular Biogenics Ltd | Methods for use of a specific anti-angiogenic adenoviral agent |
| JP6009357B2 (ja) * | 2010-01-12 | 2016-10-19 | バスキュラー バイオジェニックス リミテッド | アデノウイルスベクターの生産方法およびそれによって生成されるウイルス調製物 |
| WO2012052878A1 (en) | 2010-10-19 | 2012-04-26 | Vascular Biogenics Ltd. | Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells |
| KR20140027063A (ko) * | 2010-10-28 | 2014-03-06 | 버지니아 커먼웰스 유니버시티 | 치료와 병용하는 암 영상화: 치료진단 |
| ES2680636T3 (es) | 2011-02-14 | 2018-09-10 | Revivicor Inc. | Cerdos genéticamente modificados para xenotrasplante de xenoinjertos vascularizados y derivados de los mismos |
| PL2908865T3 (pl) | 2012-10-17 | 2019-08-30 | Vascular Biogenics Ltd. | Adenowirus wykazujący ekspresję chimery Fas i jego zastosowanie w sposobach leczenia raka |
| EP2951307B1 (en) | 2013-02-04 | 2019-12-25 | Vascular Biogenics Ltd. | Methods of inducing responsiveness to anti-angiogenic agent |
| CN107630004B (zh) | 2017-09-01 | 2021-01-15 | 康希诺生物股份公司 | 降低可复制性腺病毒产生的细胞株及构建方法和应用 |
| JP2021500355A (ja) | 2017-10-20 | 2021-01-07 | バスキュラー バイオジェニックス リミテッド | 抗血管新生薬剤療法のための診断方法 |
| KR20210139329A (ko) | 2019-03-13 | 2021-11-22 | 바스큘라 바이오제닉스 리미티드 | 항종양 요법의 방법 |
| MX2021012398A (es) | 2019-04-12 | 2021-11-12 | Vascular Biogenics Ltd | Metodos de terapia antitumoral. |
| CN110714028B (zh) * | 2019-11-04 | 2021-08-31 | 中国人民解放军第四军医大学 | 可控性上调Ang-(1-7)靶向性防治低氧性肺动脉高压的表达载体 |
| CN114457003A (zh) | 2020-11-10 | 2022-05-10 | 维思尔治疗有限公司 | 预调节血管细胞用于转导的方法、转导方法和保存转导的细胞的方法 |
| CA3232376A1 (en) * | 2021-09-20 | 2023-03-23 | Maria KOKKINAKI | Multitransgenic pigs comprising ten genetic modifications for xenotransplantation |
| FR3158516A1 (fr) * | 2024-01-23 | 2025-07-25 | Asfalia Biologics | Production de vecteurs toxiques |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US207985A (en) * | 1878-09-10 | Improvement in grain-separators | ||
| US4866042A (en) * | 1987-11-18 | 1989-09-12 | Neuwelt Edward A | Method for the delivery of genetic material across the blood brain barrier |
| US5464764A (en) * | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| US6337209B1 (en) * | 1992-02-26 | 2002-01-08 | Glaxo Wellcome Inc. | Molecular constructs containing a carcinoembryonic antigen regulatory sequence |
| CA2108144A1 (en) * | 1991-03-06 | 1992-09-07 | Jack A. Roth | Methods and compositions for the selective inhibition of gene expression |
| US5635385A (en) * | 1993-09-15 | 1997-06-03 | Temple University-Of The Commonwealth System Of Higher Education | Multi-unit ribozyme inhibition of oncogene gene expression |
| US6037329A (en) * | 1994-03-15 | 2000-03-14 | Selective Genetics, Inc. | Compositions containing nucleic acids and ligands for therapeutic treatment |
| US6579697B1 (en) * | 1995-05-11 | 2003-06-17 | Yeda Research And Development Co. Ltd. | Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors |
| US8715645B2 (en) * | 1994-05-27 | 2014-05-06 | The Regents Of The University Of Colorado | Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same |
| US5906827A (en) * | 1994-06-03 | 1999-05-25 | Creative Biomolecules, Inc. | Matrix for the manufacture of autogenous replacement body parts |
| US5747340A (en) * | 1994-06-03 | 1998-05-05 | Syntex (U.S.A.) Inc. | Targeted gene expression using preproendothelin-1 promoters |
| GB9506466D0 (en) * | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| US5734039A (en) * | 1994-09-15 | 1998-03-31 | Thomas Jefferson University | Antisense oligonucleotides targeting cooperating oncogenes |
| US5712149A (en) * | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| US5792453A (en) * | 1995-02-28 | 1998-08-11 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
| EA001616B1 (ru) * | 1995-02-28 | 2001-06-25 | Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ | Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре |
| US5916763A (en) * | 1995-11-09 | 1999-06-29 | The Regents Of The University Of California | Promoter for VEGF receptor |
| AU719629B2 (en) * | 1996-11-08 | 2000-05-11 | Oklahoma Medical Research Foundation | Endothelium specific expression regulated by EPCR control elements |
| AU741439B2 (en) * | 1996-12-30 | 2001-11-29 | Battelle Memorial Institute | Formulation and method for treating neoplasms by inhalation |
| US6206917B1 (en) * | 1997-05-02 | 2001-03-27 | St. Jude Medical, Inc. | Differential treatment of prosthetic devices |
| ES2320603T3 (es) * | 1997-07-30 | 2009-05-25 | Emory University | Sistemas de expresion, vectores, adn, proteinas de mineralizacion osea novedosos. |
| EP0909532A1 (en) * | 1997-10-16 | 1999-04-21 | Development Center For Biotechnology | Environmentally compatible porous material comprising beneficial nematodes and its preparation |
| JP2001521786A (ja) * | 1997-10-30 | 2001-11-13 | ザ ジュネラル ホスピタル コーポレーション | 単離軟骨細胞を使用した軟骨性基質の接着 |
| US5882893A (en) * | 1997-12-04 | 1999-03-16 | Millennium Pharmaceuticals, Inc. | Nucleic acids encoding muscarinic receptors and uses therefor |
| US6417168B1 (en) * | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
| CA2331844A1 (en) * | 1998-05-07 | 1999-11-11 | University Of Maryland, Baltimore | A method for diagnosing and treating chronic pelvic pain syndrome |
| US6239151B1 (en) * | 1998-06-26 | 2001-05-29 | Hoffmann-La Roche Inc. | Compounds as inhibitor of tumor necrosis factor alpha release |
| US6545048B1 (en) * | 1999-06-29 | 2003-04-08 | California Institute Of Technology | Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity |
| US6576265B1 (en) * | 1999-12-22 | 2003-06-10 | Acell, Inc. | Tissue regenerative composition, method of making, and method of use thereof |
| US6479064B1 (en) * | 1999-12-29 | 2002-11-12 | Children's Medical Center Corporation | Culturing different cell populations on a decellularized natural biostructure for organ reconstruction |
| US6376244B1 (en) * | 1999-12-29 | 2002-04-23 | Children's Medical Center Corporation | Methods and compositions for organ decellularization |
| US6265216B1 (en) * | 2000-01-20 | 2001-07-24 | Isis Pharmaceuticals, Inc. | Antisense modulation of cot oncogene expression |
| US6866864B2 (en) * | 2000-03-20 | 2005-03-15 | Ahmed Mousa | Compositions and methods of use in the treatment of angiogenesis and vascular-related disorders |
| US6652583B2 (en) * | 2000-04-07 | 2003-11-25 | Rhode Island Hospital | Cardiac valve replacement |
| AU2003222427B8 (en) * | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| US8071740B2 (en) * | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| US8039261B2 (en) * | 2000-11-17 | 2011-10-18 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| US20100282634A1 (en) * | 2000-11-17 | 2010-11-11 | Dror Harats | Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis |
| ES2425321T3 (es) * | 2000-11-17 | 2013-10-14 | Vascular Biogenics Ltd. | Promotores que muestran especificidad por células endoteliales y métodos de utilización de los mismos |
| US7067649B2 (en) * | 2000-11-17 | 2006-06-27 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| EP1207205A1 (en) * | 2000-11-20 | 2002-05-22 | Crucell Holland B.V. | Adenoviral replicons |
| US6438802B1 (en) * | 2001-06-07 | 2002-08-27 | Randolph Scott Beeman | Locking mechanism and method for securely fastening resilient cords and tubing |
| CN1195056C (zh) * | 2001-07-12 | 2005-03-30 | 钱其军 | 一种在肿瘤细胞中特异性增殖及高效表达抗癌基因的重组病毒及其构建方法 |
| CN100506284C (zh) * | 2001-10-19 | 2009-07-01 | 脉管生物生长有限公司 | 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法 |
| US9738907B2 (en) * | 2002-02-01 | 2017-08-22 | Oxford Biomedica (Uk) Limited | Viral vector |
| AU2003244347A1 (en) * | 2002-02-04 | 2003-09-02 | Takeda Chemical Industries, Ltd. | Angiogenesis inhibitors |
| CN1424401A (zh) * | 2003-01-06 | 2003-06-18 | 李川源 | 有条件复制型腺病毒及其构建方法和用途 |
-
2007
- 2007-04-30 US US11/790,992 patent/US20070286845A1/en not_active Abandoned
-
2008
- 2008-04-27 AU AU2008243817A patent/AU2008243817B2/en not_active Ceased
- 2008-04-27 NZ NZ581511A patent/NZ581511A/en not_active IP Right Cessation
- 2008-04-27 CN CN2013100850374A patent/CN103276015A/zh active Pending
- 2008-04-27 WO PCT/IL2008/000543 patent/WO2008132729A2/en not_active Ceased
- 2008-04-27 JP JP2010505002A patent/JP2010525805A/ja active Pending
- 2008-04-27 MX MX2009011750A patent/MX2009011750A/es active IP Right Grant
- 2008-04-27 EP EP08738245A patent/EP2152317A4/en not_active Withdrawn
- 2008-04-27 CN CN200880022935A patent/CN101808669A/zh active Pending
- 2008-04-27 CA CA002685394A patent/CA2685394A1/en not_active Abandoned
- 2008-04-27 KR KR1020097024041A patent/KR101525548B1/ko not_active Expired - Fee Related
-
2009
- 2009-11-25 ZA ZA2009/08331A patent/ZA200908331B/en unknown
-
2013
- 2013-10-21 US US14/059,426 patent/US20140155467A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010525805A5 (https=) | ||
| CN108546717A (zh) | 反义lncRNA介导顺式调控抑制靶基因表达的方法 | |
| JP2012010710A5 (https=) | ||
| JP2009539367A5 (https=) | ||
| US8916378B2 (en) | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulations of angiogenesis and anticancer therapy | |
| García-Moruja et al. | Functional characterization of SDF-1 proximal promoter | |
| JP2009219504A5 (https=) | ||
| JP2010259439A5 (https=) | ||
| CN103981155B (zh) | 靶向肝癌溶瘤腺病毒的构建法和应用 | |
| Cherian et al. | An activating mutation of interferon regulatory factor 4 (IRF4) in adult T-cell leukemia | |
| Cao et al. | Gene therapy for hepatocellular carcinoma based on tumour-selective suicide gene expression using the alpha-fetoprotein (AFP) enhancer and a housekeeping gene promoter | |
| Shirakawa et al. | A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells | |
| JP2005523718A5 (https=) | ||
| JP2018509154A5 (https=) | ||
| CA2478616A1 (en) | Use of adenoviruses mutated in the va genes for cancer treatment | |
| NO330666B1 (no) | Selektivt replikerende, rekombinant virusvektor, farmasoytisk formulering, fremgangsmate for dreping av en celle ex vivo med en reaksjonsveimangel, anvendelse av en selektivt replikerende viral vektor for fremstilling av et farmasoytisk preparat, samt fremgangsmate for fremstilling av en selektivt replikerende viral vektor. | |
| Ulasov et al. | Oncolytic adenoviruses: a thorny path to glioma cure | |
| Curtin et al. | Turning the gene tap off; implications of regulating gene expression for cancer therapeutics | |
| CN1259106C (zh) | 一种抗癌靶向基因病毒药物的制备方法 | |
| Ding et al. | Cytidine deamination and cccDNA degradation: A new approach for curing HBV? | |
| JP2021505634A5 (https=) | ||
| CN108018267A (zh) | 一种靶向表观基因调控抗乙型肝炎病毒分子HBx1C及其应用 | |
| JP4402457B2 (ja) | アデノウイルスｅ２後期プロモーターの制御のための、インビトロにおけるｙｂ−１の使用、及び、腫瘍の治療を目的とする医薬の製造のための当該使用を活用した核酸構築物の使用 | |
| JP2009535031A5 (https=) | ||
| Lyra-González et al. | Adenoviral gene therapy in hepatocellular carcinoma: a review |